ImmuPharma Extends Incanthera Warrants to 2025

ImmuPharma (GB:IMM) has released an update.

ImmuPharma PLC, a drug discovery and development company, has announced an extension of their Warrant Instrument with Incanthera plc until 31 March 2025, following a cash payment of £75,000 to secure the extension. The company believes in the robust investment case of Incanthera and foresees potential share price accretion as Incanthera meets key milestones. ImmuPharma, which has managed its cash efficiently, has opted for warrant extension over immediate exercise to maintain financial prudence.

For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.